<DOC>
	<DOC>NCT02322866</DOC>
	<brief_summary>To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris</brief_summary>
	<brief_title>Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety &amp; Efficacy of Sarecycline in Treatment of Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Signed informed consent or assent form Male/female, 9 to 45 years of age, inclusive Body weight between 33 and 136 kg, inclusive Facial acne vulgaris with: 2050 inflammatory lesions (papules, pustules and nodules) 30100 noninflammatory lesions (open and closed comedones) No more than 2 nodules IGA score of moderate (3) or severe (4) Negative urine pregnancy test at baseline females of childbearing potential Agrees to use an effective method of contraception throughout the study Refrain from use of any other acne medications and medicated cleansers, and avoid excessive sun exposure and tanning booths for duration of study Able to fulfill the requirements of protocol, indicated willingness to participate in the study and agrees to all study procedures (including mandatory photography) by providing written informed consent/assent and an authorization to disclose protected health information (PHI) Has a dermatological condition of the face that could interfere with the clinical evaluations Has a history of any of the following: Allergy to tetracyclineclass antibiotics or to any ingredient in the study drug Pseudomembranous colitis or antibioticassociated colitis Treated for any type of cancer within the last 6 months Has known resistance to other tetracyclines Has receive any of the following treatments within 12 weeks of screening: Systemic retinoids Systemic corticosteroids Androgens/antiandrogenic therapy (eg, anabolic steroids, spironolactone) Nonmedicated procedures for the treatment of acne (eg, laser, light or ThermaClear) Has used any acne affecting treatment without an appropriate washout period Has initiated hormonal contraceptive use within 12 weeks prior to screening or plans to initiate or switch hormonal contraceptive products during the study period Is pregnant, lactating or planning a pregnancy during the study period Has any other disorder causing hyperandrogenism including, but not limited to polycystic ovary syndrome, adrenal or ovarian tumors, Cushings disease or congenital adrenal hyperplasia Has druginduced acne Has significant intercurrent illness, psychiatric disposition or other factors that, in the opinion of the Investigator or Medical Monitor, precludes participation in the study Is currently participating, or has participated within 30 days prior to the screening period in an investigational drug or device study Has previously participated in any clinical trial involving the use of sarecycline Is judged by the Investigator to be unsuitable for any reason</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>acne</keyword>
</DOC>